Evolving treatments for migraine prevention

At EAN 2022, Cristina Tassorelli, Professor of Neurology, University of Pavia, Italy, discussed that non-migraine-specific oral preventive treatments that have been used for migraine include beta-blockers, calcium antagonists, anti-depressants, and anti-convulsants. However, while of use for some, ineffectiveness and the side-effect profile of some of these medications may limit use. More recently, migraine-specific monoclonal antibodies have been developed that target a neuropeptide involved with vasodilation and nociceptor receptor activation, linked with pain and other migraine symptoms. Combined, these older and newer treatments mean there is an increasing armamentarium for preventive migraine treatment.

Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country